Virological characteristics of the SARS‐CoV‐2 Omicron EG.5.1 variant
Microbiology and Immunology · 2024
DOI: 10.1111/1348-0421.13165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2024. Verfasst von Shuhei Tsujino und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, Phylogeny, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Core Research for Evolutional Science and Technology.
Abstract (Originalsprache)
In middle to late 2023, a sublineage of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron XBB, EG.5.1 (a progeny of XBB.1.9.2), is spreading rapidly around the world. We performed multiscale investigations, including phylogenetic analysis, epidemic dynamics modeling, infection experiments using pseudoviruses, clinical isolates, and recombinant viruses in cell cultures and experimental animals, and the use of human sera and antiviral compounds, to reveal the virological features of the newly emerging EG.5.1 variant. Our phylogenetic analysis and epidemic dynamics modeling suggested that two hallmark substitutions of EG.5.1, S:F456L and ORF9b:I5T are critical to its increased viral fitness. Experimental investigations on the growth kinetics, sensitivity to clinically available antivirals, fusogenicity, and pathogenicity of EG.5.1 suggested that the virological features of EG.5.1 are comparable to those of XBB.1.5. However, cryo‐electron microscopy revealed structural differences between the spike proteins of EG.5.1 and XBB.1.5. We further assessed the impact of ORF9b:I5T on viral features, but it was almost negligible in our experimental setup. Our multiscale investigations provide knowledge for understanding the evolutionary traits of newly emerging pathogenic viruses, including EG.5.1, in the human population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
- Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
- First Medical Faculty at Biocev, Charles University, Vestec-Prague, Czechia.
- Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU (UCH-CEU), CEU Universities, Valencia, Spain.
- Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Förderung
- Core Research for Evolutional Science and Technology
Zitieren
APA
Tsujino, S., Deguchi, S., Nomai, T., Padilla-Blanco, M., Plianchaisuk, A., Wang, L., Begum, M. M., Uriu, K., Mizuma, K., Nao, N., Kojima, I., Tsubo, T., Li, J., Matsumura, Y., Nagao, M., Oda, Y., Tsuda, M., Anraku, Y., Kita, S., …, & Genotype to Phenotype Japan (G2P‐Japan) Consortium (2024). Virological characteristics of the SARS‐CoV‐2 Omicron EG.5.1 variant. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.13165
Vancouver
Tsujino S, Deguchi S, Nomai T, Padilla-Blanco M, Plianchaisuk A, Wang L, et al. Virological characteristics of the SARS‐CoV‐2 Omicron EG.5.1 variant. Microbiology and Immunology. 2024. doi:10.1111/1348-0421.13165
BibTeX
@article{Tsujino2024,
author = {Tsujino, Shuhei and Deguchi, Sayaka and Nomai, Tomo and Padilla-Blanco, Miguel and Plianchaisuk, Arnon and Wang, Lei and Begum, Mst Monira and Uriu, Keiya and Mizuma, Keita and Nao, Naganori and Kojima, Isshu and Tsubo, Tomoya and Li, Jingshu and Matsumura, Yasufumi and Nagao, Miki and Oda, Yoshitaka and Tsuda, Masumi and Anraku, Yuki and Kita, Shunsuke and Yajima, Hisano and Sasaki-Tabata, Kaori and Guo, Ziyi and Hinay, Alfredo A and Yoshimatsu, Kumiko and Yamamoto, Yuki and Nagamoto, Tetsuharu and Asakura, Hiroyuki and Nagashima, Mami and Sadamasu, Kenji and Yoshimura, Kazuhisa and Nasser, Hesham and Jonathan, Michael and Putri, Olivia and Kim, Yoonjin and Chen, Luo and Suzuki, Rigel and Tamura, Tomokazu and Maenaka, Katsumi and Irie, Takashi and Matsuno, Keita and Tanaka, Shinya and Ito, Jumpei and Ikeda, Terumasa and Takayama, Kazuo and Zahradnik, Jiri and Hashiguchi, Takao and Fukuhara, Takasuke and Sato, Kei and Genotype to Phenotype Japan (G2P‐Japan) Consortium, Genotype to Phenotype Japan (G2P‐Japan) Consortium},
title = {Virological characteristics of the SARS‐CoV‐2 Omicron EG.5.1 variant},
journal = {Microbiology and Immunology},
year = {2024},
doi = {10.1111/1348-0421.13165}
}
EUVIMED